KYTHERA Biopharmaceuticals (FRA:KYT) 5-Year Yield-on-Cost % : 0.00 (As of May. 08, 2024)

View and export this data going back to . Start your Free Trial

What is KYTHERA Biopharmaceuticals 5-Year Yield-on-Cost %?

KYTHERA Biopharmaceuticals's yield on cost for the quarter that ended in Jun. 2015 was 0.00.

The historical rank and industry rank for KYTHERA Biopharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:

FRA:KYT's 5-Year Yield-on-Cost % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.195
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of KYTHERA Biopharmaceuticals's 5-Year Yield-on-Cost %

For the Drug Manufacturers - General subindustry, KYTHERA Biopharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KYTHERA Biopharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KYTHERA Biopharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where KYTHERA Biopharmaceuticals's 5-Year Yield-on-Cost % falls into.

KYTHERA Biopharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of KYTHERA Biopharmaceuticals is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

KYTHERA Biopharmaceuticals (FRA:KYT) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

KYTHERA Biopharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of KYTHERA Biopharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

KYTHERA Biopharmaceuticals (FRA:KYT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KYTHERA Biopharmaceuticals Inc (FRA:KYT) » Definitions » 5-Year Yield-on-Cost %

Traded in Other Exchanges

N/A

Address

Website

http://www.kytherabiopharma.com

KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.

KYTHERA Biopharmaceuticals (FRA:KYT) Headlines

No Headlines